Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T14:25:58.201Z.
Calculation as of: 2026-10-06T14:25:58.201Z.
Quote observation: 2026-10-06T14:25:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: de430a97f2ce1d56e5593aeaf7513a4829955f1ae9df1fe435740c279e59bff8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Hemab Therapeutics Holdings, Inc. Common Stock
Market Cap
$1.32B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.41B
Price/OCF Ratio
78.19
TTM Avg
254.68
3Y Avg
254.68
5Y Avg
167.20
Market Cap
$1.21B
Price/OCF Ratio
18.74
TTM Avg
22.01
3Y Avg
32.46
5Y Avg
37.26
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $1.32B | N/A | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.36B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 78.19 | 254.68 | 254.68 | 167.20 |
| Cronos Group Inc. (CRON)vs › | $1.22B | 20.24 | 36.33 | 71.26 | 71.26 |
| Innovage Holding Corp. (INNV)vs › | $1.21B | 18.74 | 22.01 | 32.46 | 37.26 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| MannKind Corporation (MNKD)vs › | $1.19B | N/A | 46.69 | 49.24 | 49.24 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | N/A | 7.14 | 7.14 | 7.14 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
